|
| Wednesday, July 19, 2017 |
|
|
HeungKong Great Health Fund I Injects HK$120 Million into Uni-Bio Science and Becomes its Strategic Shareholder |
| Uni-Bio Science Group Limited ("Uni-Bio Science", "Uni-Bio" or the "Group"; HKEx code: 690) today announced that HeungKong Great Health Fund I, led by the famed Mainland China-based corporation HeungKong Group, has invested HK$120 million in the Group and become its strategic shareholder. more info >> |
|
| Monday, February 27, 2017 |
|
|
Uni-Bio Science's Drugs Officially Reimbursed under the National Reimbursement Drug List |
| Uni-Bio Science Group Limited ("Uni-Bio Science" or the "Group;" HKEx code: 690) has announced that its product Mitiglinide is now to be officially reimbursed under the National Reimbursement Drug List ("NRDL") published by Ministry of Human Resources and Social Security today. more info >> |
|
| Friday, August 26, 2016 |
|
|
Uni-Bio Science Group Announces 2016 Interim Results |
| Uni-Bio Science Group Limited ("Uni-Bio Science" or the "Group"; HKEx code: 690) has announced its interim results for the six months ended 30 June 2016. more info >> |
|
| Monday, June 27, 2016 |
|
|
Uni-Bio Science Group Forges Strategic Alliance with China Resources Zizhu for GeneSoft |
| Uni-Bio Science Group Ltd (HKEx: 690) announced that it has signed a strategic alliance agreement with China Resources Zizhu Pharmaceutical Co., Ltd. more info >> |
|
| Tuesday, June 14, 2016 |
|
|
Uni-Bio Science Group Announces 2015 Annual Results |
| Uni-Bio Science Group Limited ("Uni-Bio Science" or the "Group"; HKEx code: 690) has announced its audited annual results for the year ended 31 December 2015. more info >> |
|
| Tuesday, March 8, 2016 |
|
|
Uni-Bio Science Completes Phase I Single Ascending Dose (SAD) Tolerability Study of Uni-EPO-Fc for Treatment of Anaemia |
Uni-Bio Science Group Limited ("Uni-Bio Science" or the "Group;" HKEx code: 690) today announced that its long-acting Human Erythropoietin-Fc fusion protein injection ("Uni-EPO-Fc") has successfully completed the single ascending dose tolerability study of the Phase I clinical trial.
more info >> |
|
| Tuesday, November 24, 2015 |
|
|
Uni-Bio Science Acquires Global Rights to Type 2 Diabetes Drug Mitiglinide from Jiangsu Hansoh Pharmaceutical Co. Ltd |
Uni-Bio Science Group Limited ("Uni-Bio" or the "Group"; HKEx code: 690) today announced that it will acquire exclusive global rights to manufacture and commercialise mitiglinide, a new oral antidiabetic agent, from Jiangsu Hansoh Pharmaceutical Co. Ltd ("Hansoh").
more info >> |
|
| Tuesday, September 8, 2015 |
|
|
Uni-Bio Science Group's Chemical Manufacturing Line in Beijing Passes GMP 2010 Standard |
Uni-Bio Science Group Limited ("Uni-Bio Science" or the "Group;" HKEx code: 690) is pleased to announce that the Group's chemical manufacturing line in Beijing has successfully passed the inspection under "Good Manufacturing Practice (2010 revision)"("GMP 2010") and received the Certificate of GMP for pharmaceutical products issued by China Food and Drug Administration ("CFDA") on 17 August 2015.
more info >> |
|
| Friday, August 14, 2015 |
|
|
Uni-Bio Science Group Announces 2015 Interim Results |
| Uni-Bio Science Group Limited ("Uni-Bio Science" or the "Group;" HKEx code: 690) has announced its interim results for the six months ended 30 June 2015. Following the bolstering of the sales and marketing teams and the Medical Function last year more info >> |
|
| Monday, August 3, 2015 |
|
|
Uni-Bio Science Group Announces Positive Phase III Results for Uni-E4 in Type-2 Diabetes |
| Uni-Bio Science Group Limited ("Uni-Bio" or the "Group";HKEx code: 690) today announced positive top-line results of the Phase III clinical trial which assessed the efficacy and safety of Uni-E4, Uni-Bio's proprietary recombinant GLP-1 receptor agonist for the treatment of Type-2 diabetes. more info >> |
|
|
|
